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Background: Protein arginine methyltransferase 6 (PRMT6) is a nuclear enzyme that methylates arginine residues
on histones and transcription factors. In addition, PRMT6 inhibits HIV-1 replication in cell culture by directly
methylating and interfering with the functions of several HIV-1 proteins, i.e. Tat, Rev and nucleocapsid (NC). PRMT6
also displays automethylation capacity but the role of this post-translational modification in its antiretroviral activity
remains unknown.
Results: Here we report the identification by liquid chromatography-mass spectrometry of R35 within PRMT6 as the
target residue for automethylation and have confirmed this by site-directed mutagenesis and in vitro and in vivo
methylation assays. We further show that automethylation at position 35 greatly affects PRMT6 stability and is
indispensable for its antiretroviral activity, as demonstrated in HIV-1 single-cycle TZM-bl infectivity assays.
Conclusion: These results show that PRMT6 automethylation plays a role in the stability of this protein and that
this event is indispensible for its anti-HIV-1 activity.
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Throughout its replication cycle, HIV interacts with a
plethora of cellular proteins that can either restrict or
aid infection. Recent genome-wide screens have identi-
fied many of the factors that contribute to HIV patho-
genesis, in particular through the regulation of HIV
protein function [1-6]. These interactions can sometimes
result in post-translational modifications that are im-
portant in the regulation of HIV proteins. For example,
acetylation of Tat regulates its transcriptional activity [7]
and serine phosphorylation is essential for the activity of
Vif [8].
Arginine methylation is a posttranslational modifica-
tion in eukaryotes that results in the covalent addition of
one or two methyl groups to the terminal nitrogen atom* Correspondence: mark.wainberg@mcgill.ca
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reproduction in any medium, provided the orof arginine [9]. This reaction is catalyzed by protein argi-
nine methyltransferases (PRMTs) and has been impli-
cated in transcriptional regulation, epigenetics, DNA
repair, mRNA splicing and signal transduction [10,11].
Arginine methylation is dependent on the methyl donor
S-adenosyl-L-methionine (SAM) to yield the methylated ar-
ginine and an S-adenosylhomocysteine [12]. Eleven PRMTs
have been characterized to date and are classified as type I,
II or III [13]. Both type I and type II produce ω-NG-
monomethylated arginine (MMA) intermediates, however
type I enzymes further catalyze the formation of ω-NG-
NG-asymmetric dimethylarginines (aDMA), while type II
enzymes catalyze NG-NG-symmetric dimethylarginines
(sDMA) [12,14]. Type III PRMTs only catalyze the forma-
tion of MMA residues. The addition of a methyl group
does not change the overall charge of a protein, but can
reallocate hydrogen bond sites, thus affecting protein-
protein interactions [15]. The importance of arginine
methylation in the cell is further supported by the factal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arginines [16].
PRMT6 is a 41.9 kDa Type I methyltransferase found
in the nucleus [17]. It typically targets arginine in glycine
and arginine rich (GAR) motifs. Thrombospondin-1
(TSP-1), H3R2 and H2A were all found to be arginine
methylated by PRMT6 [18-20]. Our group has found
that PRMT6 methylates and restricts the function of the
HIV proteins Tat, Rev, and Nucleocapsid (NC) [21-24],
resulting in restriction of HIV-1 replication by PRMT6.
Methylation of Tat by PRMT6 leads to a disruption of
the Tat-TAR-cyclin T1 complex and decreases Tat specific
transcriptional activation [21]. Once NC is methylated by
PRMT6, it is less able to promote RNA annealing and ini-
tiate reverse transcription [24].
The HIV-1 Rev protein is a 19 kDa protein found in
the nucleolus, the perinuclear zone, and the cytoplasm
of HIV infected cells. It mediates viral protein expression
at the level of viral RNA splicing and nuclear export of
unspliced and single spliced viral RNA by binding to
the cis-acting Rev response element (RRE) [25,26].
Rev is arginine methylated by PRMT6 in its arginine
rich motif (ARM) located within the Rev nuclear
localization signal (NLS) [23]. Rev-mediated export of viral
RNA is decreased when Rev is methylated by PRMT6 be-
cause methylated Rev is unable to bind efficiently to the
RRE [23].
Automethylation of PMRT6 has been reported [17],
but the site and role of automethylation have not been
identified. PRMT6 requires homodimerization to trans-
fer a methyl group from SAM to the protein substrate
and this could favour automethylation [27]. As docu-
mented for CARM1 (PRMT4), another member of the
PRMT family, we have hypothesized that automethylation
could modulate PRMT6 function [28]. Mutagenesis of
the automethylation site of CARMI did not affect its cata-
lytic activity but impaired its transcriptional and RNA-
processing capacity. Additionally, arginine methylation of
the HIV protein Tat by PRMT6 and of the cellular protein
axin by PRMT1 increase the stability of these proteins
[29,30]. We now report that R35 is crucial for PRMT6
automethylation and that arginine automethylation is im-
portant for PRMT6 stability and its ability to inhibit HIV-
1 replication.
Results
Identification of PRMT6 automethylation sites in vitro and
in vivo
PRMT6 was previously shown to be automethylated [17].
Now, we wished to identify the arginine residues that are
involved and, therefore, used purified recombinant PRMT6
in an in vitromethylation assay in the presence and absence
of the methyl group donor S-adenosyl-methionine (SAM)
with catalytically inactive recombinant PRMT6 V86K/D88A(PRMT6-KLA) serving as a control. Post-translational
methylation was determined by mass spectrometry and
showed that R29, R35 and R37 in the N-terminal region
of the protein were methylated in the PRMT6 wild-type
protein with and without SAM but not in the KLA in-
active mutant (Figure 1A). Extracting ions from the pep-
tides that contain R35 from both proteins confirmed the
absence of methylation on this residue within the KLA mu-
tant (Figure 1B). The observation that PRMT6-WT was
methylated in the absence of added substrate suggested that
most of the active protein was automethylated during bacte-
rial expression and also provided an explanation for the low
levels of automethylation observed in previous studies [17].
We also confirmed that R35 is methylated in vivo by
conducting an in vivomethylation assay (Figure 1E).
Alignment studies show that the R35, R37, and R38 resi-
dues are well conserved among mammals e.g. Homo sapiens,
Pan troglodytes, Macaca mulatta, Sus scrofa, Mus musculus,
Rattus norvegicus, and Bos Taurus (Figure 2), but the region
is not conserved in some other organisms, e.g. Arabidopsis
thaliana and Danio rerio (data not shown), suggesting that
its emergence followed the divergence that occurred be-
tween these branches in evolution. R29 is poorly evolu-
tionary conserved.
PRMT6 is automethylated at R35
To characterize the role of automethylation in the acti-
vity of PRMT6, the central residue R35 was mutated
to an alanine residue (PRMT6-R35A) and automethylation
was measured in vitro in the presence of 3H-SAM
(Figure 3). Mutant PRMT6-KLA was used as a negative
control. Weak but consistent automethylation was mea-
sured for the wild-type recombinant PRMT6 protein but
not for either KLA or R35A, suggesting that R35 plays a
critical role in automethylation. Therefore our study fo-
cused on the role of this residue. In a similar experi-
ment, PRMT6-R35A was shown to be able to methylate
the purified HIV-1 Rev protein in vitro, indicating
that this mutated derivative protein retains its ability
to arginine methylate other proteins but not itself
(Figure 4). In the same experiment, PRMT6-KLA was,
as expected, completely unable to methylate Rev. Thus,
R35 is a PRMT6 primary automethylation site and
automethylation may not be essential for the methyla-
tion of HIV-1 Rev. We performed similar in vitro
methylation experiments using HIV-1 Tat as a substrate
and found that PRMT6-R35A maintains methylation
activity (data not shown).
PRMT6 automethylation regulates its stability
We next measured the stability of the wild-type, KLA,
and R35A PRMT6 proteins (Figure 5). Plasmids coding
for the various forms of myc-tagged PRMT6 were
transfected into HeLa cells, and, at 24 h after transfection,
PRMT6 WT (Coverage 44%)
*      * *
MSQPKKRKLE SGGGGEGGEG TEEEDGAERE AALERPRRTK RERDQLYYEC YSDVSVHEEM IADRVRTDAY RLGILRNWAA
LRGKTVLDVG AGTGILSIFC AQAGARRVYA VEASAIWQQA REVVRFNGLE DRVHVLPGPV ETVELPEQVD AIVSEWMGYG 
LLHESMLSSV LHARTKWLKE GGLLLPASAE LFIAPISDQM LEWRLGFWSQ VKQHYGVDMS CLEGFATRCL MGHSEIVVQG
LSGEDVLARP QRFAQLELSR AGLEQELEAG VGGRFRCSCY GSAPMHGFAI WFQVTFPGGE SEKPLVLSTS PFHPATHWKQ 
ALLYLNEPVQ VEQDTDVSGE ITLLPSRDNP RRLRVLLRYK VGDQEEKTKD FAMED
PRMT6 WT + SAM (Coverage 57%)
*      * *
MSQPKKRKLE SGGGGEGGEG TEEEDGAERE AALERPRRTK RERDQLYYEC YSDVSVHEEM IADRVRTDAY RLGILRNWAA
LRGKTVLDVG AGTGILSIFC AQAGARRVYA VEASAIWQQA REVVRFNGLE DRVHVLPGPV ETVELPEQVD AIVSEWMGYG 
LLHESMLSSV LHARTKWLKE GGLLLPASAE LFIAPISDQM LEWRLGFWSQ VKQHYGVDMS CLEGFATRCL MGHSEIVVQG 
LSGEDVLARP QRFAQLELSR AGLEQELEAG VGGRFRCSCY GSAPMHGFAI WFQVTFPGGE SEKPLVLSTS PFHPATHWKQ 
ALLYLNEPVQ VEQDTDVSGE ITLLPSRDNP RRLRVLLRYK VGDQEEKTKD FAMED
PRMT6 MUTANT (10x) (Coverage 52%)
MSQPKKRKLE SGGGGEGGEG TEEEDGAERE AALERPRRTK RERDQLYYEC YSDVSVHEEM IADRVRTDAY RLGILRNWAA
LRGKTKLAVG AGTGILSIFC AQAGARRVYA VEASAIWQQA REVVRFNGLE DRVHVLPGPV ETVELPEQVD AIVSEWMGYG 
LLHESMLSSV LHARTKWLKE GGLLLPASAE LFIAPISDQM LEWRLGFWSQ VKQHYGVDMS CLEGFATRCL MGHSEIVVQG 
LSGEDVLARP QRFAQLELSR AGLEQELEAG VGGRFRCSCY GSAPMHGFAI WFQVTFPGGE SEKPLVLSTS PFHPATHWKQ 
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PRMT6 in vivo (Coverage 63%)
*      * **
MSQPKKR
E
KLE SGGGGEGGEG TEEEDGAERE AALERPRRTK RERDQLYYEC YSDVSVHEEM IADRVRTDAY RLGILRNWAA 
*
LRGKTVLDVG AGTGILSIFC AQAGARRVYA VEASAIWQQA REVVRFNGLE DRVHVLPGPV ETVELPEQVD AIVSEWMGYG 
LLHESMLSSV LHARTKWLKE GGLLLPASAE LFIAPISDQM LEWRLGFWSQ VKQHYGVDMS CLEGFATRCL MGHSEIVVQG 
LSGEDVLARP QRFAQLELSR AGLEQELEAG VGGRFRCSCY GSAPMHGFAI WFQVTFPGGE SEKPLVLSTS PFHPATHWKQ 
ALLYLNEPVQ VEQDTDVSGE ITLLPSRDNP RRLRVLLRYK VGDQEEKTKD FAMED
CTLb #1042 RT: 10.10 AV: 1 NL: 6.93E3
T: ITMS + c NSI d Full ms2 471.26@cid35.00 [115.00-955.00]
WTb #1025 RT: 8.08 AV: 1 NL: 9.63E2
T: ITMS + c NSI d Full ms2 485.28@cid35.00 [120.00-985.00]
Figure 1 Mass spectrometric analysis of PRMT6 arginine methylated residues. Following in vitro and in vivo methylation, methylated
arginine residues in recombinant PRMT6 were mapped by LC-MS/MS. (A) Percent coverage obtained for PRMT6 WT (−/+ SAM) and the PRMT6
KLA mutant. Recombinant PRMT6 was digested with Trypsin in an ammonium bicarbonate buffer and peptides were separated onto a C18
column and sequenced by LC-MS (Methods). To evaluate trace amounts of dimethylated arginine in mutated protein, a 10 fold concentrated
peptide solution was injected. Percentages coverage for PRMT6, PRMT6 + SAM and the PRMT6 mutant were 44%, 57%, and 52%, respectively
(highlighted in green). Dimethylated arginine was identified only with PRMT6 WT +/− SAM (R29; R35; R37). Dimethylated residues are represented
with an (*) above the residue. (B) To evaluate the percentage of dimethylated arginine on PRMT6, ions corresponding to EAALERPR (m/z 471.26)
and EAALER*PR (m/z 485.27) were extracted. Dimethylation was only observed in the WT protein and in the WT protein + SAM (not shown).
There was no detectable signal at m/z 485.27 in the PRMT6 KLA mutant even when used at 10-fold the WT protein concentration. Areas under
the curve (AUC) were studied for both peptides from the PRMT6 WT protein; assuming no differences in ionization efficiency, the methylated
protein apparently represents 10 to 20% of total protein. MS/MS spectra observed for the methylated (C) EAALERPR and non-methylated (D)
peptide of wild type PRMT6. Observed ions are indicated in bold. (E) In vivo methylation assays were performed in HeLa cells with transfected
myc-tagged PRMT6. Samples were digested and processed as described for the in vitro methylation assays. The percent coverage for PRMT6-WT
was 63% (highlighted in green). Dimethylated arginines were identified for residues R29, R35, R38, R39 and R82, and are represented with an (*).
Amino acids mutated in PRMT6-KLA are indicated by enlarged letters.
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tants. Since CHX inhibits protein synthesis, it can be
used to study protein degradation over time in studies
in which expression levels of PRMT6 protein are mea-
sured by Western-blot. The results show that PRMT6
is very stable (Figure 5A, first panel), but that themutant R35A protein and the catalytically inactive KLA
form of PRMT6 were less stable, with their expression
levels decreasing over time. Densitometric quantifica-
tion of the Western-blot confirmed that the expression
levels of both mutant proteins decreased faster than
the WT protein following the addition of CHX
Figure 2 The R35 residue is conserved in evolution. Sequence
alignment of PRMT6 proteins from various organisms showing
conservation of the arginine residue at position 35 (H. sapiens). The
consensus sequence was produced using ClustalW2 (http://www.ebi.
ac.uk/Tools/msa/clustalw2/). R35 is bolded and the underlined text
refers to the arginine rich motif.
10 kDa
10kDa
Figure 4 PRMT6-R35A is catalytically active. A PRMT6 cell-free
methylation assay was performed with HIV-1 Rev protein, a known
substrate of PRMT6. The upper frame represents the autoradiograph
of Rev methylation by PRMT6. The lower frame represents a
Coomassie stained gel of Rev. This experiment was performed three
times with similar results obtained each time; a representative result
is shown.
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ant for its stability.
PRMT6 automethylation is required for inhibition of HIV-1
replication
We have shown that the expression level of PRMT6 is
important for inhibition of HIV-1 replication, and now
wished to assess the impact of the R35A mutation on
this activity (Figure 6). Proviral DNA coding for pNL4-3
virus was co-transfected into 293T cells together with ei-
ther a control empty plasmid or plasmids coding for
PRMT6-WT or R35A mutant proteins. The resulting vi-
ruses were quantified by RT activity assay and by QPCR
(Figure 6A and B) and their infectiousness was tested
in TZM-bl reporter cells by normalizing the amount
of infecting virus for either RT activity or viral RNA
(Figure 6C and D). Since PRMT6-WT and R35A display
differences in their stability (Figure 5), we verified the70 kDa
70 kDa
Figure 3 PRMT6-R35A does not automethylate. Cell-free
automethylation assays were performed using the indicated PRMT6
recombinant proteins in the presence of 3H-SAM. Autoradiography
(upper) and Coomassie staining (lower) are shown. 3H-SAM was
contained in all wells. The first lane contains methylation buffer only,
without the presence of PRMT6. The other lanes contain the
indicated recombinant proteins. This experiment was performed
three times with similar results being obtained each time; a
representative result is shown.proper expression of these proteins in these experi-
ments by measuring PRMT6 protein expression at
24 hours post transfection by Western blot (Figure 6E).
Densitometric quantification indicated that PRMT6-
WT expression levels were 20% lower than those of
PRMT6-R35A in these experiments, measures that are
independent from differences in stability. The data
show that expression of PRMT6-WT decreased HIV-1
infectivity, but that the R35A mutation restored viral
infectivity to levels similar to those of virus grown in
the absence of PRMT6. This indicates that prevention
of PRMT6 automethylation results in a significant de-
crease in PRMT6 anti-HIV activity of approximately
90% (Figure 6).
Discussion
Although PRMT6 is known to be able to restrict the ac-
tivity of the HIV-1 Tat, NC, and Rev proteins as well as
viral replication, the role of PRMT6 automethylation in
this process has been unknown. Additionally, the iden-
tity of the residue(s) targeted for automethylation has
remained elusive. Here, we have shown that R29, R35,
and R37 of PRMT6 are auto-dimethylated, as demon-
strated in a cell-free reaction. PRMT6 automethylation
sites were confirmed in vivo. Mutating R35 to an alanine
resulted in the inhibition of PRMT6 automethylation.
We have further shown that automethylation is re-
quired for PRMT6 protein stability and its anti-HIV-1
activity. This is important as several inhibitors of
PRMT proteins are currently being developed for can-
cer therapy and could also have potential for treatment
of HIV infection [31].
Major host restriction factors (HRFs) that control HIV
replication in specific cell types include TRIM5α,
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Figure 5 PRMT6-R35A is less stable than PRMT6-WT. (A) Western blots for Myc-PRMT6-WT, PRMT6-R35A and PRMT6-KLA, following treatment
with CHX (upper panels). Actin was used as a loading control (lower panels). 15 μg of protein from whole cell extract were loaded into each well.
(B) Densitometric analysis of Myc-PRMT6-WT and -R35A degradation over time following the addition of CHX. Myc expression was normalized to
levels of actin. Each experiment was performed three times with similar results obtained each time; a representative blot is shown.
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i.e. phosphorylation and ubiquitination for APOBEC3G
[32-34]. The current study reinforces the fact that argin-
ine methylation can play a role in regulation of anti-HIV
activity, and, in addition, is the first to identify R35 as a
major residue targeted for automethylation within PRMT6.
Finally, preventing PRMT6 automethylation by introducing
the R35A mutation antagonized the antiretroviral effects of
this protein, demonstrating that PRMT6-mediated anti-
HIV activity is both specific and that this activity is regu-
lated in vivo.
To identify potential methylated arginines, we performed
mass spectrometric analysis on recombinant PRMT6-WT
and PRMT6-KLA. These studies led to the identifica-
tion of three arginine residues, i.e. R29, R35, and R37
in the N-terminal region of PRMT6 that are specifically
methylated in the WT protein but not in the KLA mu-
tant. This indicated that these residues are modified
through automethylation. Additionally, we show here that
PRMT6 is automethylated in the absence of added SAM,
suggesting that most of PRMT6 was automethylated
during bacterial expression. This may provide an explan-
ation for the low levels of PRMT6 in vitro automethylation
reported previously [17]. Other related enzymes including
PRMT1, CARM1 and PRMT8 have all been described
as possessing automethylation activity [28,35,36]. In
similar fashion to PRMT6, as shown here, CARM1automethylation has been shown to be dispensable for its
enzymatic activity in vitro, but can still affect the ability of
the enzyme to activate transcription and to regulate pre-
mRNA splicing [28].
Following CHX treatment, both the methyltransferase
deficient PRMT6-KLA mutant and the PRMT6 R35A
mutant displayed considerably less stability than did
WT PRMT6. Arginine methylation has been linked
to protein stability in several previous studies. For ex-
ample, PRMT1 arginine methylation of axin increases
the stability of the latter by blocking ubiquitination [30].
PRMT3 methylation of the 40S ribosomal protein S2
(rpS2) also increases protein stability by reducing rpS2
ubiquitination [37]. Importantly, PRMT6 methylation has
been shown to increase the half-life of the HIV-1 Tat
protein without changing its ubiquitination pattern [29].
We are currently trying to determine whether the en-
hanced degradation of PRMT6-KLA and PRMT-R35A
may also be due to ubiquitination.
Our findings further show that methylated PRMT6 is
able to restrict HIV-1 replication whereas the ability of
R35A-PRMT6 to play this role is diminished by as
much as 90% (Figure 6A and B). Since PRMT6-R35A
has intact catalytic activity in vitro, we believe that its di-
minished restriction activity may be due to a reduced
availability of mutated PRMT6 within the cell, as a result
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Figure 6 PRMT6 automethylation is necessary for its HIV-1 restriction activity. The indicated forms of PRMT6 plasmid were co-transfected
with HIV-1 pNL4.3 proviral DNA into 293T cells. At 48 hours after transfection, cell culture fluids containing virus were collected, quantified by
QPCR (A) or by HIV RT activity assay (B), and titrated onto TZM-bl cells (C, D). The amount of transfected PRMT6 expression, i.e. not protein
stability, was quantified by Western blots with anti-Myc and anti-actin antibodies followed by densitometric analysis normalized against actin (E).
Endogenous levels of PRMT6 in HeLa cells (lane 2), TZM-bl cells (lane 3) and 293T cells (lane 4) were compared to transfected PRMT6 in HeLa
cells (lane 1) (F). 15 μg of protein from whole cell extracts were loaded into each well used for analysis in the Western blots in (E) and (F). Actin
was used as a loading control. Infectivity was measured by luciferase assay at 48 hours after infection. The control experiment was transfection of
pNL4.3 with an empty plasmid (referred to on the figure as pNL4.3 only). Each experiment was performed in triplicate on three separate
occasions, with similar results being obtained each time. T-tests were performed for both (A) and (B), showing that only PRMT6-WT was
significantly different than the control *: p < 0.05. Two-way ANOVA was performed for (C) and (D), showing that only PRMT6-WT statistically
inhibited HIV replication *: p < 0.001.
Singhroy et al. Retrovirology 2013, 10:73 Page 6 of 10
http://www.retrovirology.com/content/10/1/73
Singhroy et al. Retrovirology 2013, 10:73 Page 7 of 10
http://www.retrovirology.com/content/10/1/73QPCR or RT activity, WT PRMT6 restriction was car-
ried over to a second cycle of infection, as shown in a
TZM-bl infectivity assay (Figure 6C and D). This sug-
gests that PRMT6 methylation affects both initial virus
production as well as subsequent rounds of replication.
A recent study reported that arginine methylation of
antigenic peptides displayed on human leukocyte antigens
(HLA) resulted in specific recognition by the immune
system and elicited a T-cell response [38]. It would be
interesting to determine whether PRMT6 methylated
HIV-1 proteins can trigger an equivalent response, as
this might represent a means of eliciting an anti-HIV-1
immunological response. Although it is clear that arginine
methylation plays an important regulatory role in protein
stability, further investigation is needed to clarify the
role that PRMTs play in regard to proteasomal degrad-
ation pathways.
Conclusion
PRMT6 is automethylated at position R35 and this event
plays an important role in regard to the stability of this pro-
tein. Due to problems of degradation of non-automethylated
PRMT6, the ability of the non-automethylated protein to




wild-type PRMT6 (GST-PRMT6-WT), methyltransferase
inactive V86K/D88A PRMT6 (GST-PRMT6-KLA) and
histidine-tagged HIV-1 Rev protein (His-Rev) were pre-
pared as described previously [23]. Myc-tagged wild-type
PRMT6 (myc-PRMT6-WT) and inactive Myc-tagged
methyltransferase V86K/D88A PRMT6 (Myc-PRMT6-
KLA) have also been described previously [22]. GST-
and Myc-tagged PRMT6-R35A mutants were generated
using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) through use of a 5′-
GCGGCCCTGGAGGCACCCCGGAGGAC-3′ forward
primer and a 5′-GTCCTCCGGGGTGCCTCCAGGGC
CGC-3′ reverse primer (Invitrogen). To quantify viral
genomic RNA, quantitative real-time polymerase chain
reaction (QPCR) primers and probe used were 5′-
CCGTCTGTTGTGTGACTCTGG- 3′ forward Primer,
5′-GAGTCCTGCGTCGAGAGATCT-3′ reverse primer
and 5′ FAM- TCTAGCAGTGGCGCCCGAACAGG-
TAMRA-3′ probe (Invitrogen) [39]. Anti-PRMT6 rabbit
polyclonal antibody was purchased from Imgenex and
anti-Myc mouse monoclonal antibody was purchased
from Invitrogen. Anti-actin mouse monoclonal antibody
was purchased from MP Biomedicals.
The following reagents were obtained through the
NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: TZM-bl from Dr. JohnC. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc and
pNL4-3 from Dr. Malcolm Martin [40].
Liquid chromatography-mass spectrometry analysis
Recombinant GST-PRMT6-WT and GST-PRMT6-KLA
(5 μg each) were incubated with 25 μM S-adenosylmethionine
(Sigma) in 25 mM Tris–HCl (pH 7.4) for 3 hours at 37°C
in a final volume of 30 μl. The reactions were stopped
by adding 6 μl of 5× Läemmli buffer, followed by boil-
ing for 5 minutes and centrifugation at 16,000 g for
2 minutes. The samples were then run on 10% SDS
polyacrylamide gels. Bands corresponding to GST-PRMT6-
WT and GST-PRMT6-KLA were cut out, processed, and
analysed by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS).
Prior to HPLC the polyacrylamide gel plug containing
GST-PRMT6 was subjected to in-gel tryptic digestion for
protein ID and identification of the dimethylated argi-
nines. Briefly the polyacrylamide gel plug was destained
with 25 mM ammonium bicarbonate (NH4HCO3) and
50% acetonitrile (ACN). The gel particle was then incu-
bated with 100% ACN. Reduction was accomplished with
10 mM DTT and alkylation with 55 mM iodoacetamide.
After washing with 50 mM NH4HCO3, the gel particles
were shrunk with 100% ACN and dried down in a
SpeedVac. In order to detect methylated peptides, samples
underwent partial in-gel digestion with 1.6 μg of Trypsin
(Sigma), an enzyme that does not digest the C-terminus of
methylated arginine. Gel particles were vortexed and soni-
cated in 5% formic acid (FA)/50% ACN to extract sample
from the gel. The volume of the sample was reduced to
15 μl in the SpeedVac and cleaned using a C18 ZipTip
(Millipore).
The samples were dried down in a SpeedVac apparatus
and resolubilized in 50 μl of acetonitrile (ACN) 5% /for-
mic acid (FA) 0.1%. 2 μl of each sample were directly
injected onto a C18 analytical column (75 μm i.d. ×
100 mm) using the Proxeon EASY nLC system. A 21-
min gradient was used to elute peptides at a flow rate of
300 nl/min. The gradient started at 3% acetonitrile/0.2%
formic acid and a linear gradient to 35% acetonitrile/
0.2% formic acid was achieved in 13 min, then ramped
up to 92% acetonitrile 0.2% formic acid after 2 minutes.
The liquid chromatography (LC) system was coupled
to a LTQ-Orbitrap mass spectrometer (MS) (Thermo
Fisher). A full MS spectrum was collected at the level of
the Orbitrap (FT-MS); then, the ten most abundant
multiply charged ions (threshold > 5000 counts) were
selected for MS/MS sequencing at the level of the linear
trap and stored in an exclusion list for 30 seconds. Tan-
dem MS experiments were performed using a collision-
induced dissociation set at 35% with activation time
of 10 msec. The data were processed using Proteome
Discoverer (version 1.3) running the SEQUEST search
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136 sequences (mostly bacterial, yeast and mammalian con-
taminants) including PRMT6 WT and mutant sequences
was performed allowing differential modification on
cysteine residues (carbamidomethylation: +58), methio-
nine (oxidation: + 16) and arginine (dimethylation: +28).
MS/MS spectra were searched for protein tryptic digests
allowing a maximum of two missed cleavage sites per pep-
tide. Only peptides with Xcorr values greater than 3.2,
equivalent to a false discovery rate lower than 1%, were
retained to assess coverage of PRMT6 (WT and Mutant)
and dimethylation sites.
In vitro methylation assay
Recombinant GST-tagged PRMT6 proteins (3–4 μg) were
incubated with 1–2 μg of recombinant histidine-tagged Rev
with 0.55 μCi of [methyl-3H]-S- adenosyl-L-methionine
(Perkin Elmer life sciences) and 25 mM Tris–HCl (pH 7.4)
for 3 hours at 37°C in a final volume of 25 μl. Reactions
were stopped by adding 5 μl of 5 × Läemmli buffer
followed by boiling for 5 minutes and centrifugation at
16,000 g for 2 minutes. Samples were loaded onto 10%
SDS polyacrylamide gels. Gels were stained with
Coomassie brilliant blue R-250 solution (Bio-Rad Labora-
tories) and, after destaining, soaked in 1× ENH3ANCE
(Perkin Elmer life sciences) for 45 minutes. Gels were
then dried and exposed on HyBlot CL autoradiography
film (Denville Scientific) for 1 to 3 days. Gels and films
were quantified with the ImageJ software [41].
Automethylation assays were similarly performed;
however, the incubation period was increased to be-
tween 14 and 21 days for reasons of enhanced
sensitivity.
In vivo methylation assay
HeLa cells were transfected with Lipofectamine 2000 reagent
according to the manufacturer’s guidelines (Invitrogen)
with 1 μg myc tagged-PRMT6 WT DNA. At 24 hr after
transfection, S-adenosyl-L-methionine (New England
Biolabs) was added to the cells. Cells were collected at
48 h post transfection and lysed with RIPA buffer, and
30 μl of lysate was then incubated with myc-conjugated
agarose beads (Sigma). After several washes, beads were
boiled in the presence of Laemmli buffer and centrifuged.
The supernatant containing the immunoprecipitated pro-
tein was run on an SDS-PAGE gel. The appropriate band
was processed for LC-MS/MS as described above.
Cell culture
HeLa, 293T and TZM-bl cells were all cultured in
Dulbecco modified Eagle medium (DMEM) (Gibco),
supplemented with 10% fetal bovine serum, 50 IU of
penicillin/ml, 50 μg of streptomycin/ml, and 2 mM L-
glutamine at 37°C in 5% CO2.Cycloheximide treatment and immunoblotting
HeLa cells were transfected with Lipofectamine 2000
reagent according to the manufacturer’s guidelines
(Invitrogen) with 1 μg myc tagged-PRMT6 WT, KLA or
R35A plasmid. At 24 hr after transfection, the cells were
treated with 100 μg/ml of cycloheximide (Sigma) and
collected after 0, 2, 4, 6 and 8 hr. Cells were lysed with
RIPA buffer containing protease inhibitor cocktail
(Sigma). Protein concentrations of whole cell extracts
were quantified using Bradford assays (5× BioRad Pro-
tein assay). 15 μg of protein was boiled with Läemmli
buffer for 5 minutes and samples were loaded onto a
10% SDS polyacrylamide gel. Western blots were
performed on a PVDF membrane (BioRad). Bands were
quantification with ImageJ (http://rsb.info.nih.gov/ij/).
Viral production and quantification
293T cells were transfected as described above. Cells
(3 × 106) were co-tranfected with 4 μg of pNL4.3 and
4 μg of myc-PRMT6 plasmids; at 48 hours post transfec-
tion, culture supernatants were collected, centrifuged at
1,200 rpm and passed through a 0.45 μm filter. Viral
particles in the supernatants were quantified by quanti-
tative real-time PCR (QPCR) as described previously
[42] and by HIV reverse transcriptase (RT) activity assay,
also previously described [43]. The same supernatants
were then used to measure infectivity in TZM-bl, as de-
scribed below. Experiments were repeated 3 separate
times and data were analysed using GraphPad Prism
software.
Infectivity assay
Viruses produced in 293T cells, as described above, in
the presence of myc-PRMT6 plasmids were normalized
on the basis of QPCR or HIV RT activity and were 5-
fold titrated onto TZM-bl luciferase reporter cells and
incubated for 48 hours. TZM-bl cells were lysed using
the luciferase assay system (Promega) and luminescence
was read with a MicroBeta Trilux Luminescence counter
over a period of 1 second (Perkin Elmer). Experiments
were repeated 3 times and data were analyzed using
GraphPad Prism software.
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